The latest price target for Avenue Therapeutics (NASDAQ:ATXI) was reported by Maxim Group on December 11, 2023. The analyst firm set a price target for $0.75 expecting ATXI to fall to within 12 months (a possible -63.77% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Avenue Therapeutics (NASDAQ:ATXI) was provided by Maxim Group, and Avenue Therapeutics initiated their buy rating.

There is no last upgrade for Avenue Therapeutics

There is no last downgrade for Avenue Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avenue Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avenue Therapeutics was filed on December 11, 2023 so you should expect the next rating to be made available sometime around December 11, 2024.

While ratings are subjective and will change, the latest Avenue Therapeutics (ATXI) rating was a initiated with a price target of $0.00 to $0.75. The current price Avenue Therapeutics (ATXI) is trading at is $2.07, which is out of the analyst’s predicted range.